Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].
References
[1] Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883. DOI:10.1158/1541-7786.MCR-16-0447
